Imperial Valley News
Dallas, Texas - The American Heart Association/American Stroke Association topped entries from 44 other countries to earn the World Stroke Organization’s First Place “Gold Award” for World Stroke Day 2014.
Atlanta, Georgia - Increasing colorectal cancer (CRC) screening rates to 80% by 2018 would prevent an additional 21,000 colorectal cancer deaths per year by 2030, according to a new study. The study is the first to estimate the public health benefits of increasing screening rates to “80% by 2018,” a recent initiative from the National Colorectal Cancer Roundtable (NCCR), a national coalition of public, private, and voluntary organizations, to aim for screening rates of 80% in the United States by 2018.
Alexandria, Virginia - Diabetes Forecast, the Healthy Living Magazine from the American Diabetes Association, has released its annual Consumer Guide with the March/April 2015 issue.
Washington, DC - Published by the American Psychological Association (APA), the new journal Scholarship of Teaching and Learning in Psychology (STLP) will feature evidence-based teaching tips and reviews of contemporary teaching theories in psychology. It plans to emphasize articles that integrate research, theory and practice to benefit high school, community college, college and university educators and their students.
Washington, DC - The U.S. Food and Drug Administration approved the ResQCPR System, a system of two devices for first responders to use while performing cardiopulmonary resuscitation (CPR) on people whose hearts stop beating (cardiac arrest). The devices may improve the patient’s chances of surviving cardiac arrest.
Washington, DC - Mutations in the presenilin-1 gene are the most common cause of inherited, early-onset forms of Alzheimer’s disease. In a new study, published in Neuron, scientists replaced the normal mouse presenilin-1 gene with Alzheimer’s-causing forms of the human gene to discover how these genetic changes may lead to the disorder. Their surprising results may transform the way scientists design drugs that target these mutations to treat inherited or familial Alzheimer’s, a rare form of the disease that affects approximately 1 percent of people with the disorder.